Mobio Interactive

AI-powered digital theragnostics platform using phone camera rPPG for personalized mental health therapy.

Website: https://www.mobiointeractive.com/


Name	Mobio Interactive
Tagline	AI-powered digital theragnostics platform using phone camera rPPG for personalized mental health therapy.
Headquarters	Singapore
Founded	2015 [PitchBook]
Stage	Seed
Business Model	B2B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$2,400,000)

Summary and Signal

Publicly reported Mobio Interactive is a nine-year-old Singaporean healthtech company building a hardware-free system to objectively measure and treat mental health conditions. This bet merits attention for its clinical validation and backing from a major strategic investor [Mobio Interactive] [Johnson & Johnson, ~2023].

The company was founded in 2015 by a team led by neuroscientist Bechara Saab to address the subjectivity of traditional mental health assessments [PitchBook] [The Org]. Its core product is a digital theragnostics platform that uses a phone's camera and remote photoplethysmography (rPPG) to quantify psychological stress from a 30-second selfie. It then delivers personalized, adaptive therapy [Mobio Interactive] [Crunchbase].

The founding team combines scientific and technical leadership. Saab serves as CEO and Chief Scientist, Avetis Muradyan as CTO. Their commercial scaling experience in enterprise healthtech is not surfaced in the public research [Mobio Interactive] [LinkedIn].

To date, the company has disclosed approximately $2.4 million in total funding, including a seed round and a grant in 2023. J&J Impact Ventures is a notable investor [MobiHealthNews] [Mobio Interactive, Aug 2023]. The business model targets B2B2C channels and aims to sell to healthcare providers, insurers, and telehealth networks seeking cost-saving preventative tools [Mobio Interactive].

The critical watchpoints over the next 12-18 months are the translation of its 20+ claimed clinical studies into named commercial deployments. Scaling its modest funding base to drive revenue growth beyond early pilot projects will also matter [Mobio Interactive] [ImpactAlpha].

Data Accuracy: YELLOW -- Core facts like founding year and investor names are corroborated, but key traction and validation metrics are sourced primarily from the company.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$2,400,000)

Company Overview

Publicly reported

Mobio Interactive was founded in 2015 in Singapore. It positions itself as a digital theragnostics company long before the recent wave of AI-driven mental health tools [PitchBook]. The founding team, led by CEO and Chief Scientist Bechara Saab, set out to address a fundamental gap in mental healthcare: the lack of objective, scalable biomarkers to personalize treatment [Mobio Interactive]. The company's core thesis, that stress and brain states could be quantified through a smartphone camera, has guided its development for nearly a decade.

Key milestones reflect a path focused on clinical validation and strategic backing. The company participated in the MedTech Innovator Asia Pacific accelerator program, a signal of its focus on regulated medical technology [Mobio Interactive, Aug 2023]. A significant inflection point was an investment from J&J Impact Ventures, the impact investing arm of Johnson & Johnson. This was announced to support the global scaling of its precision psychiatry platform [Johnson & Johnson, ~2023].

In August 2023, Mobio announced it had secured a grant [Mobio Interactive, Aug 2023]. The company also formed a Growth Advisory Board in 2024 to guide its next phase of commercial expansion [Mobio Interactive].

Data Accuracy: YELLOW -- Founding year and location corroborated by PitchBook; key milestones and team roles cited from company sources and a J&J press release.

The Product and the Stack

Public record plus analysis The core product is a digital theragnostics platform that uses a smartphone camera to measure psychological stress. It aims to replace subjective self-reports with objective, hardware-free biomarkers.

Mobio Interactive's platform is built on remote photoplethysmography (rPPG) technology. The system analyzes subtle changes in facial blood flow from a 30-second selfie video to quantify brain states associated with stress and anxiety [Mobio Interactive]. This data is then used to personalize and adapt digital psychotherapy programs. The company calls this process "digital theragnostics" [Mobio Interactive].

The company claims its approach has generated more than 3.5 million datapoints from over 425,000 selfie scans [ImpactAlpha]. The product is designed for integration into telehealth networks, hospital systems, and insurance platforms. It targets both clinicians and patients directly in a B2B2C model [Mobio Interactive].

The technical differentiation rests on the proprietary rPPG algorithm and the associated clinical validation. Mobio Interactive states its methods are supported by 20+ clinical studies and 19 peer-reviewed papers [Mobio Interactive]. The platform's output is intended to serve as a scalable, objective measure for prevention, real-time assessment, and treatment monitoring [Mobio Interactive].

Data Accuracy: YELLOW -- Core product claims are sourced from the company's website and a secondary press article. Key traction metrics (scans, datapoints) and clinical validation counts are company-reported.

Market Research and Opportunity

Publicly reported The market for digital mental health tools is expanding rapidly. It is driven by a persistent global treatment gap and growing acceptance of technology for scalable, objective care.

The global digital therapeutics market was valued at approximately $5.1 billion in 2022. It is projected to grow at a compound annual growth rate of 26.1% through 2030, according to a Grand View Research report [Grand View Research, 2023].

Within this, the segment for AI-powered mental health platforms represents a significant and fast-growing portion. The company's focus on hardware-free, biomarker-driven assessment positions it within the precision psychiatry niche. This niche aims to address the subjectivity inherent in traditional diagnostic methods.

Key demand drivers for this category are well-documented. The global burden of mental health conditions continues to rise. Healthcare systems face severe provider shortages, creating pressure for scalable, lower-cost interventions.

The shift towards value-based care and preventive health models creates a financial incentive for tools that demonstrate measurable outcomes and cost savings, particularly among insurers and large employers. Mobio's targeting of payors and telehealth networks aligns directly with these tailwinds [Mobio Interactive].

Mobio's wedge of using ubiquitous smartphone cameras attempts to bypass the adoption friction and cost associated with dedicated devices. Regulatory forces are a critical factor. Achieving regulatory approvals as a Software as a Medical Device (SaMD) or digital therapeutic in key markets like the United States, Europe, and Singapore is a significant hurdle [Mobio Interactive].

Market Segment	Cited Size (Year)	Source	Notes
Global Digital Therapeutics	$5.1B (2022)	Grand View Research	Analogous market; projected 26.1% CAGR to 2030.

Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report; company-specific TAM/SAM/SOM is not publicly disclosed.

The Competitive Field

Public record plus analysis

Mobio Interactive operates in a competitive map defined by the intersection of digital mental health, biometric sensing, and therapeutic delivery. Its primary claim to distinction rests on a hardware-free, camera-based measurement technique.

Competitive Map by Segment

The company's offering touches several distinct competitive segments, each with its own set of incumbents and challengers.

In the digital therapeutic (DTx) software segment, direct competitors include companies like Woebot Health and Big Health. They deliver structured, evidence-based cognitive behavioral therapy (CBT) and other interventions via mobile applications.

The biometric sensing for mental health segment includes companies utilizing wearables (e.g., Oura Ring for stress, Empatica for physiological monitoring) and other contact-based sensors to provide objective data. Mobio's rPPG approach positions it as a challenger here.

Adjacent substitutes include traditional telehealth and therapy platforms (BetterHelp, Talkspace) and enterprise wellness suites (Calm for Business, Headspace Health).

Defensible Edge and Durability

Mobio's current edge appears to be technological and regulatory. The company claims a proprietary dataset of over 425,000 scans and 3.5 million datapoints derived from its rPPG technology. This forms the foundation for its AI models [Mobio Interactive].

The claim of "clinically validated in 20+ studies" and 19 peer-reviewed papers suggests an early focus on regulatory and scientific credibility. This is a significant barrier in medical technology [Mobio Interactive].

Exposure and Vulnerabilities

The company's most significant exposure is its go-to-market and scale. After nine years of operation and with approximately $2.4 million in total disclosed funding, Mobio lacks the capital war chest of well-funded DTx or wellness platforms that have raised hundreds of millions [Crunchbase, MobiHealthNews].

18-Month Scenario

The most plausible competitive scenario over the next 18 months hinges on partnership execution and regulatory progress. The winner in this segment will likely be the company that successfully embeds its technology into a high-volume clinical or payer workflow. It would move from pilot to scaled deployment.

Data Accuracy: YELLOW -- Competitor landscape analysis is based on public market knowledge; Mobio's specific claims of clinical validation and dataset size are sourced solely from the company.

Opportunity

Publicly reported The prize for Mobio Interactive is the potential to become the first widely adopted, hardware-free standard for objective mental health assessment and therapy. It would turn the subjective, self-reported nature of psychiatric care into a quantifiable, data-driven discipline.

The headline opportunity is for Mobio to define the category of digital theragnostics. It would become the default platform for payors and providers seeking to manage mental health costs with objective biomarkers.

This outcome is reachable because the company's core technical wedge, remote photoplethysmography (rPPG) via smartphone camera, addresses a fundamental gap in the market: the lack of scalable, objective measures for mental states [Mobio Interactive]. Its validation in over 20 clinical studies provides a foundation of scientific credibility [Mobio Interactive].

The backing from J&J Impact Ventures, an investor with deep pharmaceutical and medical device distribution channels, signals that a major industry player sees a path to scaling this technology [Johnson & Johnson, ~2023].

Scenario	What happens	Catalyst	Why it's plausible
Payor-Led Prevention	Health insurers and employers embed Mobio's assessment tools into wellness programs to reduce claims for stress-related conditions.	A major insurance provider in Asia-Pacific announces a partnership covering Mobio's platform for a large member base.	The company explicitly targets payors for "cost-saving prevention" and has a dedicated section of its website outlining this value proposition [Mobio Interactive].
Telehealth Integration	Mobio's rPPG technology becomes a standard feature within major telehealth platforms, providing clinicians with an objective vital sign for mental health during virtual consultations.	Integration with a leading telehealth network in a key market like Singapore or Australia.	The platform is designed for remote use and targets "telehealth networks" as a core customer segment.
Government Public Health Deployment	A national health service adopts Mobio's tools for population-level mental health screening, particularly in schools or primary care settings.	A pilot program funded by a government health ministry leads to a broader procurement contract.	The company's mission emphasizes "infrastructural impact in global mental health" [Mobio Interactive].

Data Accuracy: YELLOW -- Core opportunity thesis is supported by company positioning and investor backing, but specific traction metrics and partnership details are limited to company sources.

Sources